A coalition of 48 states and territories has locked in a $29.6 million settlement with generic drug manufacturer Glenmark Pharmaceuticals over accusations that the company conspired with rivals to inflate prices on dozens of generic prescriptions. A federal court in Connecticut granted preliminary approval to the deal on August 7, 2026, moving the case a step closer to actually paying out money to consumers who bought the affected drugs. The settlement adds to nearly $67 million already collected from other manufacturers caught up in the same multistate investigation.
What Glenmark Is Accused of Doing
Connecticut Attorney General William Tong has led the coalition since the investigation began in 2016, and the case against Glenmark accuses the company of joining a web of generic drug makers who met at industry dinners, golf outings and cocktail parties, then followed up with phone calls, emails and texts to coordinate pricing. According to Attorney General Tong’s office, investigators built the case on more than 20 million documents and phone records tied to over 600 sales and pricing employees across the industry, including a two-volume notebook in which one cooperating witness recorded his conversations with competitors over several years.
Court filings describe defendants using coded language like “fair share,” “playing nice in the sandbox” and “responsible competitor” to describe how they allegedly discouraged competition and kept prices high across a broad swath of generic drugs. The investigation grew out of a first complaint filed in 2016 naming Heritage Pharmaceuticals and 17 other companies, followed by a 2019 complaint against Teva Pharmaceuticals and 21 more manufacturers, and a third complaint focused on 80 topical generic drugs that together account for billions of dollars in annual U.S. sales.
Glenmark has agreed to pay $25 million plus interest over four years, totaling $29,668,000, and to cooperate in the broader litigation still moving toward trial. That litigation now targets 33 corporate defendants and 25 individual executives, several of whom, along with two former Heritage executives, have already agreed to cooperate as witnesses. States expect the first trial in that set of cases to begin in Hartford, Connecticut, later in 2026.
Free retirement updates: Keep more of your Social Security and savings with plain-English updates on the changes, deadlines, and costly mistakes retirees miss. Subscribe free.
Five Manufacturers, One Purchase Window
The restitution fund isn’t limited to Glenmark’s own products. Anyone who purchased a generic prescription drug made by Glenmark, Lannett, Bausch, Apotex or Heritage between May 2009 and December 2019 may qualify for a share, according to a separate announcement from the New Jersey Attorney General’s office. Those five companies were named because each has now reached its own settlement stemming from the same set of price-fixing complaints, with Lannett, Bausch, Apotex and Heritage’s combined $66.95 million already secured before Glenmark’s deal brought the total past $96 million.
Eligibility runs by drug purchase, not by dollar amount or receipt, which is why the states are framing this as a broad consumer program rather than a narrow refund tied to a specific product recall. Nearly every state and territory joined the coalition behind the case, from Alaska and California to Puerto Rico and the U.S. Virgin Islands, and each will distribute its share of the fund to residents who filled a qualifying prescription. Consumers do not need to produce an old pharmacy receipt to find out whether they qualify; the states have set up a dedicated eligibility line and website to sort that out instead.
Registering Now, Before Any Claim Form Opens
People who think they qualify can call 1-866-290-0182, email info@AGGenericDrugs.com or visit AGGenericDrugs.com to register and check eligibility. That step is separate from filing an actual claim for money — the claim form tied to the Glenmark settlement has not opened, and a payout timeline won’t be set until the settlement clears final court approval, which typically follows preliminary approval by several months while the notice period runs and objections are resolved.
Consumers who register now should expect updates directly from the settlement administrator through the official site rather than unsolicited calls or texts asking for payment or bank details, since no legitimate part of this process charges a fee to participate. Because the case is still working through the courts, the amount any individual household eventually receives will depend on how many people register and file once a claim form does open, not on a fixed per-person dollar figure announced today.
A Fund Still Growing as More Manufacturers Settle
Glenmark’s payment is the fifth settlement to come out of Connecticut’s generics investigation, following deals with Heritage, Apotex, Bausch and Lannett that state officials say already total $66.95 million. Vermont’s Attorney General’s office noted that its residents have separately been alerted to potential restitution tied to this specific Glenmark payout, a pattern likely to repeat as each state issues its own consumer notice over the coming weeks. As part of the settlement, Glenmark also agreed to a series of internal compliance reforms intended to prevent the kind of coordination with competitors that triggered the case in the first place.
The next major development to watch is the Hartford trial against the manufacturers still fighting the states’ claims, a proceeding Connecticut’s office says has been years in the building since the first complaint named Heritage Pharmaceuticals and 17 other companies back in 2016.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- What really happens to your joint savings account when you die?
- Bank statements: how long to keep them and when to toss them
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
